Phase 4
N=177
Drug Therapy for Generalized Anxiety Disorder Among the Elderly
Anxiety Disorders · Generalized Anxiety Disorder
Bottom Line
View on ClinicalTrials.gov: NCT00105586 ↗Enrolled (actual)
177
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Response Using Clinical Global Impressions-Improvement Scale (CGI-I) — 51; 69 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Escitalopram (Drug)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- University of Pittsburgh
- Primary completion
- Jan 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Response Using Clinical Global Impressions-Improvement Scale (CGI-I) |
51; 69 | — |
| SECONDARY Quality of Life |
42.19; 53.42; 62.50; 56.16 | — |
Summary
This study will determine the efficacy of escitalopram (Lexapro®), an anti-anxiety drug, for generalized anxiety disorder (GAD) and the ways genetics affect response to treatment for GAD in elderly individuals.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of at least moderately severe generalized anxiety disorder (GAD)
Exclusion Criteria
- Serious suicide risk or psychiatric instability that would affect study participation
- Dementia
- Substance abuse, such as alcoholism, within 6 months prior to study entry
- Diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or bipolar disorder
- Unstable medical conditions that would preclude the use of escitalopram
- Use of certain psychotropics that can not be safely tapered or discontinued for at least 2 weeks prior to and during the study
- Use of neuroleptics that are absorbed over a prolonged period of time within 6 weeks prior to study entry
Data sourced from ClinicalTrials.gov (NCT00105586). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.